JP2022518236A5 - - Google Patents
Info
- Publication number
- JP2022518236A5 JP2022518236A5 JP2021541607A JP2021541607A JP2022518236A5 JP 2022518236 A5 JP2022518236 A5 JP 2022518236A5 JP 2021541607 A JP2021541607 A JP 2021541607A JP 2021541607 A JP2021541607 A JP 2021541607A JP 2022518236 A5 JP2022518236 A5 JP 2022518236A5
- Authority
- JP
- Japan
- Prior art keywords
- shows
- tumors
- cells
- tumor
- resistant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794896P | 2019-01-21 | 2019-01-21 | |
| US62/794,896 | 2019-01-21 | ||
| US201962926379P | 2019-10-25 | 2019-10-25 | |
| US62/926,379 | 2019-10-25 | ||
| EP19306471.4 | 2019-11-14 | ||
| EP19306471 | 2019-11-14 | ||
| PCT/US2020/014039 WO2020154189A1 (en) | 2019-01-21 | 2020-01-17 | Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022518236A JP2022518236A (ja) | 2022-03-14 |
| JP2022518236A5 true JP2022518236A5 (https=) | 2023-02-07 |
Family
ID=69582159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541607A Ceased JP2022518236A (ja) | 2019-01-21 | 2020-01-17 | 進行期固形腫瘍がんに対する治療用ｒｎａおよび抗ｐｄ１抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220288199A1 (https=) |
| EP (1) | EP3914355A1 (https=) |
| JP (1) | JP2022518236A (https=) |
| KR (1) | KR20210118870A (https=) |
| CN (1) | CN113507963A (https=) |
| AU (1) | AU2020210614A1 (https=) |
| BR (1) | BR112021013965A2 (https=) |
| CA (1) | CA3126110A1 (https=) |
| IL (1) | IL284645A (https=) |
| MX (1) | MX2021008605A (https=) |
| SG (1) | SG11202107396RA (https=) |
| TW (1) | TWI850316B (https=) |
| WO (1) | WO2020154189A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202428301A (zh) | 2017-02-28 | 2024-07-16 | 法商賽諾菲公司 | 治療性rna |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| SG11202106764YA (en) | 2018-12-27 | 2021-07-29 | Gigagen Inc | Anti-ctla-4 binding proteins and methods of use thereof |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020154187A1 (en) * | 2019-01-21 | 2020-07-30 | Sanofi | Therapeutic rna for advanced stage solid tumor cancers |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN116194142A (zh) | 2020-09-03 | 2023-05-30 | 瑞泽恩制药公司 | 通过施用pd-1抑制剂治疗癌症疼痛的方法 |
| WO2022090203A1 (en) * | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| EP4232068A1 (en) * | 2020-10-26 | 2023-08-30 | Cytune Pharma | IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
| WO2023279068A1 (en) * | 2021-07-02 | 2023-01-05 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
| EP4261217A4 (en) | 2022-02-28 | 2024-09-11 | Guangzhou Henovcom Bioscience Co., Ltd. | Compound for rna capping and application of compound |
| CN115260264B (zh) * | 2022-02-28 | 2023-06-09 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| US10131712B2 (en) * | 2012-08-14 | 2018-11-20 | Ibc Pharmaceuticals, Inc. | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CN108064176A (zh) * | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| CN109715205A (zh) * | 2016-08-19 | 2019-05-03 | 库瑞瓦格股份公司 | 用于癌症治疗的rna |
| TW202428301A (zh) * | 2017-02-28 | 2024-07-16 | 法商賽諾菲公司 | 治療性rna |
| JP2020514370A (ja) * | 2017-03-17 | 2020-05-21 | キュアバック アーゲー | 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤 |
| WO2020154187A1 (en) * | 2019-01-21 | 2020-07-30 | Sanofi | Therapeutic rna for advanced stage solid tumor cancers |
-
2020
- 2020-01-17 AU AU2020210614A patent/AU2020210614A1/en not_active Abandoned
- 2020-01-17 EP EP20705267.1A patent/EP3914355A1/en not_active Withdrawn
- 2020-01-17 WO PCT/US2020/014039 patent/WO2020154189A1/en not_active Ceased
- 2020-01-17 SG SG11202107396RA patent/SG11202107396RA/en unknown
- 2020-01-17 CA CA3126110A patent/CA3126110A1/en active Pending
- 2020-01-17 CN CN202080010292.0A patent/CN113507963A/zh active Pending
- 2020-01-17 TW TW109101808A patent/TWI850316B/zh active
- 2020-01-17 KR KR1020217026319A patent/KR20210118870A/ko not_active Withdrawn
- 2020-01-17 JP JP2021541607A patent/JP2022518236A/ja not_active Ceased
- 2020-01-17 BR BR112021013965-6A patent/BR112021013965A2/pt not_active Application Discontinuation
- 2020-01-17 MX MX2021008605A patent/MX2021008605A/es unknown
-
2021
- 2021-07-06 IL IL284645A patent/IL284645A/en unknown
- 2021-07-20 US US17/380,251 patent/US20220288199A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022518236A5 (https=) | ||
| Ylösmäki et al. | Design and application of oncolytic viruses for cancer immunotherapy | |
| Yang et al. | T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems | |
| Ferris et al. | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation | |
| Doo et al. | Checkpoint inhibitors in ovarian cancer: A review of preclinical data | |
| Rodriguez-Ruiz et al. | Immune mechanisms mediating abscopal effects in radioimmunotherapy | |
| Hashimoto et al. | The suppression of metastases and the change in host immune response after low-dose total-body irradiation in tumor-bearing rats | |
| Bartneck et al. | Roles of CCR2 and CCR5 for hepatic macrophage polarization in mice with liver parenchymal cell-specific NEMO deletion | |
| US20230134650A1 (en) | Methods of treating cancer with interferon wherein the cancer cells are hla negative or have reduced hla expression | |
| Dougan et al. | Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity | |
| Kim et al. | Combined NK cell therapy and radiation therapy exhibit long-term therapeutic and antimetastatic effects in a human triple negative breast cancer model | |
| Finkelstein et al. | Combining immunotherapy and radiation for prostate cancer | |
| AU2018228308A1 (en) | Anticancer composition comprising tumor-specific oncolytic adenovirus and immune checkpoint inhibitor | |
| KR20190096936A (ko) | 암 치료를 위하여 tlr9 작용제를 사용한 면역 조정 | |
| Reijmen et al. | Fractionated radiation severely reduces the number of CD8+ T cells and mature antigen presenting cells within lung tumors | |
| JP2022518235A5 (https=) | ||
| Chung et al. | DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth | |
| US10980859B2 (en) | In vivo individualized systemic immunotherapeutic method and device | |
| Shimizu et al. | Systemic DC activation modulates the tumor microenvironment and shapes the long-lived tumor-specific memory mediated by CD8+ T cells | |
| Zhu et al. | Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies | |
| Quaglino et al. | ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas | |
| Olivera et al. | Regional and intratumoral adoptive T-cell therapy | |
| Petriv et al. | Essential roles of B cell subsets in the progression of MASLD and HCC | |
| Fujinami et al. | Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model | |
| Li et al. | Tertiary lymphoid structures: allies of cancer immunotherapy |